EUVIMEDEUVIMED entdecken
Open Access

A new Anticalin protein for IL-23 inhibits non-type 2 allergen-driven mouse lung inflammation and airway hyperresponsiveness

Thayse R Brüggemann iD, Nandini Krishnamoorthy iD, Matthias Hagner iD, Gabriele Matschiner, Thomas Jaquin iD, Luciana P Tavares iD, Hong Yong Peh, Bruce D Levy iD

American Journal of Physiology-Lung Cellular and Molecular Physiology · 2024

DOI: 10.1152/ajplung.00295.2023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Physiology-Lung Cellular and Molecular Physiology, 2024. Verfasst von Thayse R Brüggemann und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass…. Hauptthemen laut MEDLINE: Interleukin-23, Pneumonia, Allergens. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI), Pieris Pharmaceuticals (Pieris).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This is the first report of an Anticalin protein engineered to neutralize IL-23 (AcIL-23). Airway administration of AcIL-23 in mice regulated allergen-driven airway inflammation, mucous cell metaplasia, and methacholine-induced airway hyperresponsiveness. In mixed granulocytic allergic lung inflammation, immune regulation of IL-23 was broader than neutralization of either IL-17 or IL-5.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-23PneumoniaAllergensAnimalsMiceInterleukin-17NeutrophilsFemaleAsthmaLungRespiratory HypersensitivityMice, Inbred BALB CAntibodies, MonoclonalMice, Inbred C57BLTh17 Cells

Stichwörter der Autor:innen

Anticalin proteinsinterleukin (IL)-23severe asthma

Substanzen

Interleukin-23AllergensInterleukin-17Antibodies, Monoclonal

Autor:innen und Institutionen

  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States.
  • Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany.

ORCID-Profile: Thayse R Brüggemann, Nandini Krishnamoorthy, Matthias Hagner, Thomas Jaquin, Luciana P Tavares, Bruce D Levy

Förderung

  • NHLBI NIH HHS
  • HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
  • Pieris Pharmaceuticals (Pieris)

Zitieren

APA

Brüggemann, T. R., Krishnamoorthy, N., Hagner, M., Matschiner, G., Jaquin, T., Tavares, L. P., Peh, H. Y., & Levy, B. D. (2024). A new Anticalin protein for IL-23 inhibits non-type 2 allergen-driven mouse lung inflammation and airway hyperresponsiveness. American Journal of Physiology-Lung Cellular and Molecular Physiology. https://doi.org/10.1152/ajplung.00295.2023

Vancouver

Brüggemann TR, Krishnamoorthy N, Hagner M, Matschiner G, Jaquin T, Tavares LP, et al. A new Anticalin protein for IL-23 inhibits non-type 2 allergen-driven mouse lung inflammation and airway hyperresponsiveness. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2024. doi:10.1152/ajplung.00295.2023

BibTeX
@article{Brggemann2024,
  author = {Brüggemann, Thayse R and Krishnamoorthy, Nandini and Hagner, Matthias and Matschiner, Gabriele and Jaquin, Thomas and Tavares, Luciana P and Peh, Hong Yong and Levy, Bruce D},
  title = {A new Anticalin protein for IL-23 inhibits non-type 2 allergen-driven mouse lung inflammation and airway hyperresponsiveness},
  journal = {American Journal of Physiology-Lung Cellular and Molecular Physiology},
  year = {2024},
  doi = {10.1152/ajplung.00295.2023}
}
Kostenlos starten →